TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05518695
Drug: BAT2022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight healthy subjects are planned to be enrolled in each group, 6 on the investigational product and 2 on placebo. Subjects will be randomized (3:1) to receive a single intravenous injection of BAT2022 for Injection or 5% glucose injection. Sentinel dosing will be performed for subjects in each group.Two subjects in each group who have received the first dose will be randomized (1:1) to either the test group or placebo group. After observation for 24 h and the drug is safe and well tolerated, the remaining subjects in this group will be randomized (5:1) to either the test group or placebo group.
Study: NCT05563389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo arm
Study: NCT05694975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The total dosage of placebo(5% glucose) for the control group is 24 g per day.
Study: NCT05258747
Drug: Lynparza® (olaparib) tablets 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lynparza® (olaparib) tablets 150 mg Manufactured for: AstraZeneca Pharmaceuticals LP, Wilmington, Delaware (DE).
Study: NCT04974814
Drug: Rosuvastatin 40mg
Normalized name: ROSUVASTATIN 40MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients in active arms will be preloaded with a single 40 mg rosuvastatin in ER before PCI
Study: NCT05323045
Drug: BYON3521
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYON3521 (in the vein) infusion every three weeks. Number of cycles: until cancer progression or unacceptable toxicity develops. Different doses.
Study: NCT04769713
Drug: Injection of normal saline in the hepatic hilum for the sham procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml sterile normal saline is injected at the hepatic hilum along the anterior surface of the portal vein within 2cm of the bifurcation.
Study: NCT05613387
Drug: ZP8396
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Participants will receive 6 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort.~Part 2: Participants will receive 16 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort. Dose up-titration will be used.
Study: NCT05864404
Drug: remimazolam-remifentanil
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the case of remimazolam, the bolus is prepared in a 30cc syringe by mixing 0.075mg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Remimazolam is then infused at 0.5 to 1 mg/kg/hr to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
Study: NCT05864404
Drug: dexmedetomidine-remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the case of dexmedetomidine, the bolus is prepared in a 30cc syringe by mixing 1.0mcg/kg and normal saline to make a total of 25mL. Inject the bolus at a rate of 150 cc/h, and measure the sedation depth every 2 to 3 minutes, stopping the infusion when the target sedation depth (RASS -1 to -2 points) is reached. Dexmedetomidine is then infused at 0.4 to 0.8 mcg/kg/h to maintain the target depth of sedation until the end of the procedure. Remifentanil was infused at a rate of 1.2-7.2 mcg/kg/h.
Study: NCT04853823
Drug: PDC-APB
Normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDC-APB Intra-muscular Injection
Study: NCT04781270
Drug: mFOLFOXIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
Study: NCT04781270
Drug: mFOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1
Study: NCT04887506
Drug: TAVT-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg abiraterone acetate granules for oral suspension in a sachet, reconstituted in water or specified fruit juice (orange juice), administered twice daily.
Study: NCT05508204
Drug: BION-1301
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution for SC injection administered as a single dose
Study: NCT05613387
Drug: Drug: Placebo (ZP8396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Participants will receive 6 once-weekly doses of placebo given subcutaneously (s.c., under the skin).~Part 2: Participants will receive 16 once-weekly doses of placebo given subcutaneously (s.c., under the skin).
Study: NCT04761952
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: daily orally
Study: NCT05638737
Drug: AZD4831
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4831
Study: NCT04037241
Drug: NLIR+FU/FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: systemic chemotherapy regimen
Study: NCT04037241
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: systemic chemotherapy regimen
Study: NCT05121389
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is injected intravenously, using a infusion rate control device to control the drip rate.
Study: NCT05184322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 15 days.
Study: NCT05184322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 6 weeks.
Study: NCT05184322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily to once weekly for 12 weeks.
Study: NCT03863145
Drug: CB-03-10
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-03-10, 100 mg capsule for oral use
Study: NCT06311903
Drug: High dose of Norepinephrine (NE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were received resuscitative fluid. If there were no response to treatment to resuscitative fluid, they received NE gradually till reach high dose (≥0.3 μg/kg/min).
Study: NCT04977570
Drug: SYHA1805 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets of SYHA1805 with three pre-designed doses
Study: NCT04977570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets of placebo with matching doses
Study: NCT05508815
Drug: Modified Zhiwang Decoction Combined with methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modified Zhiwang Decoction 100 ml (twice, per day) and methotrexate (7.5-15mg, once a week) for 12 weeks.
Study: NCT05508815
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate(7.5-15mg, once a week) for 12 weeks.
Study: NCT05759962
Drug: LQT-1213
Approvals — FDA: no, EMA: no, PMDA: no
Description: LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
Study: NCT05624723
Drug: INCB054707
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB054707 75 mg will be administered orally
Study: NCT06456489
Drug: Solumedrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg methylprednisolone intravenous pulse on 2 consecutive days
Study: NCT05575297
Drug: Methotrexate Sodium
Normalized name: Methotrexate Sodium
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate oral administration alone
Study: NCT04953962
Drug: CBP501 (25)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m2
Study: NCT05428449
Drug: GT20029 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
Study: NCT05428449
Drug: GT20029 Gel Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage 1: One single dose Stage 2: One single dose per day (QD) or twice a day (BID) treatment over 14-day period
Study: NCT04415853
Drug: Lerotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 50 mg/capsule and 150 mg/capsule
Study: NCT06026553
Drug: Ketorolac (Toradol)
Normalized name: ketorolac tromethamine Injectable Solution [Toradol]
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Ketorolac (Toradol) will be administered at conclusion of oocyte retrieval. All enrolled patients will receive standard post-operative pain management.
Study: NCT04840342
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose escalations of eplerenone 50, 100, or 200mg
Study: NCT06164535
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 T2DM patients will be given placebo (only adjust their drugs to control blood glucose level)
Study: NCT06198751
Drug: 6.0 mg/kg of TQB2102 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 6.0 mg/kg.
Study: NCT06198751
Drug: 7.5 mg/kg of TQB2102 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC), 7.5 mg/kg.
Study: NCT04591379
Drug: Influenza Vaccines
Normalized name: Influenza vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral application of an unattenuated influenza vaccine
Study: NCT04845399
Drug: Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received prophylaxis treatment at 50 IU/ kg every three days.30-50 IU/kg is recommended to administration while bleeding occurs during the experiment.
Study: NCT05127759
Drug: HLX208
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX208 450mg bid po
Study: NCT05318846
Drug: HRS4800 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing frequency: single dose; Route of administration: oral
Study: NCT05318846
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing frequency: single dose; Route of administration: oral
Study: NCT00046306
Drug: Antioxidants
Normalized name: E Complex with Antioxidants
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06470477
Drug: Guideline-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based treatment includes anti-platelet therapy, control of vascular risk factors, and so on.
Study: NCT05518071
Drug: CRGD-ZW800-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous single bolus injection of the targeted NIR fluorophore cRGD-ZW800-1. This targeted 800nm zwitterionic fluorophore developed by the Hospital Pharmacy Department of LUMC consists of the fluorophore ZW800-1 conjugated to the cRGD peptide
Study: NCT00001039
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05851924
Drug: NALIRIFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive NALIRIFOX for a total of 4 months. NALIRIFOX will be administered on days 1 and 15 of a 4-week cycle for 4 cycles until completion of therapy, intolerable toxicity, or until the development of criteria for removal from the study.~Liposomal irinotecan: 50 mg/m2 IV over the course of 90 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Oxaliplatin: 60 mg/m2 IV over the course of 120 minutes (±10 minutes) on days 1 and 15 of every 4-week cycle.~Leucovorin: 400 mg/m2 IV over the course of 30 minutes (±5 minutes) on days 1 and 15 of every 4-week cycle.~5-FU: 2400 mg/m2 IV over the course of 48 hours (or until the infusion is complete) on days 1 and 15 of every 4-week cycle
Study: NCT06405685
Drug: AG
Normalized name: AGP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive AG as conversion therapy up to 6 months. Gemcitabine 1000 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle. nab-Paclitaxel 125 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.
Study: NCT06395883
Drug: Glucocorticoid Effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.
Study: NCT05492305
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with any GLP1 receptor agonist e.g. liraglutide, semaglutide, dulaglutide for either obesity or type 2 diabetes mellitus
Study: NCT06082570
Drug: c610 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1 positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptors. The obtained c610 is used for one-time intravenous infusion.
Study: NCT05238831
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05407285
Drug: cannabis 0 mg, placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
Study: NCT05262452
Drug: FOLFIRINOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: a chemotherapy regimen for treatment of advanced pancreatic cancer~* FOL : folinic acid (leucovorin), a vitamin B derivative that enhances the effects of 5-FU~* F : 5-FU, a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis~* IRIN : irinotecan (eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.~* OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis
Study: NCT05407285
Drug: Cannabis 20 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible participant will be randomize 1:1:1:1:1 to receive study products in a prefilled single syringe with 2 ml of product solution with varying amounts of CBD (0 - 20 mg - 50 mg -100 mg - 200 mg. Only one research product will be ingested at each visit. The sequence will depend on the assigned randomization group.
Study: NCT05317442
Drug: Fespixon Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Name: Fespixon Cream~2. Dosage form: Topical cream, 15 g ointment per tube~3. Active ingredients: 1.25% extracts of Plectranthus amboinicus (PA-F4, 0.25%) and Centella asiatica (S1, 1%)~4. Dose(s): Apply 1 cc per 5 cm\^2 ulcer size (not exceeding 2 mm in thickness)~5. Dosing schedule: Apply once a day~6. Duration: up to 16 weeks
Study: NCT05492851
Drug: Synvisc-One 48 MG in 6 ML Prefilled Syringe
Normalized name: Synvisc-One 48 MG in 6 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection to treat knee osteoarthritis
Study: NCT05492851
Drug: Monovisc 88 MG Per 4 ML Prefilled Syringe
Normalized name: Monovisc 88 MG per 4 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection to treat knee osteoarthritis
Study: NCT05752526
Drug: Diclofenac 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal hydrogel containing 1% Diclofenac
Study: NCT05752526
Drug: Diclofenac 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal hydrogel containing 3% Diclofenac
Study: NCT06121804
Drug: Immunosuppressive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribing immunosuppressive agents
Study: NCT05292053
Drug: TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
Normalized name: TRELEGY ELLIPTA 100mcg-62.5mcg-25mcg/actuation Powder for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder)
Study: NCT04014244
Drug: Corticosteroid vs. Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: US guided injection of corticosteroid in one hand and 5% glucose in the other will be performed in accordance with randomization. In a syringe both substances will be diluted using 0.9% NaCl to a total injection volume of 6 ml. In-plane ulnar approach will be used to visualize the median nerve at the level of the pisiform bone. A standard 23 gauge needle will be inserted in the carpal tunnel with the needle tip positioned between retinaculum and median nerve.
Study: NCT05521412
Drug: [ 161 Tb]Tb PSMA I&T
Approvals — FDA: no, EMA: no, PMDA: no
Description: During dose escalation, doses of \[161 Tb\]Tb PSMA I\&T will range between 4.4 GBq to 7.4 GBq. The recommended phase 2 dose of \[161 Tb\]Tb PSMA I\&T will be used during dose expansion. \[161Tb\]Tb-PSMA-I\&T dose will be reduced by 0.4 GBq for each subsequent cycles (2 to 6).
Study: NCT05742230
Drug: blank control
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment
Study: NCT05408923
Drug: (0.05% chlorhexidine gluconate (CHG) in sterile water)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group will get Irrisept irrigation (0.05% CHG in sterile water) throughout the case.
Study: NCT05858684
Drug: GC012F injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive GC012F injection (CD19-BCMA CAR-T cells) by intravenous infusion on Day 0.
Study: NCT04758234
Drug: LY3549492
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04758234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05034068
Drug: 0.15% bezaydamine hydrochloride.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% bezaydamine hydrochloride was applied in oral mucosa in Patients with head and neck cancer under RT, CT treatment.
Study: NCT06018727
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 20 mg capsule will be administered orally.
Study: NCT06018727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebos will be administered orally.
Study: NCT04592159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oromucosal spray
Study: NCT05876390
Drug: analgesia
Normalized name: Analgesia Creme Rub
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia
Study: NCT06413953
Drug: TQB3107 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3107 tablets is protein inhibitor that inhibit tumor cell proliferation, and induce apoptosis, thereby exerting anti-tumor effects.
Study: NCT04843579
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given as 500 mg oral capsule
Study: NCT05163223
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection
Study: NCT05163223
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On days 1-14 (Q3W), BID ; Oral administration,
Study: NCT04829435
Drug: ALLN-346
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration; It is a proprietary enzyme designed to degrade urate in the intestinal tract
Study: NCT04829435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
Study: NCT05274204
Drug: CA102N
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05408247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT04955249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group receive routine patient-controlled intravenous analgesia for up to 3 days after surgery. The formula is a mixture of placebo and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
Study: NCT00899587
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05445856
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl is administered as a single intravenous dose after induction of anesthesia and prior to initiation of surgery
Study: NCT01351168
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CD/LD 25/100, 2 tablets test dose based on subject's current CD/LD dosing; single randomized testing day
Study: NCT04711603
Drug: MR13A9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT04711603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT05106205
Drug: DA-5213-R 10mg
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (one tablet once a day)
Study: NCT04789577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received two doses of Placebo by intramuscular injection in the non-dominant arm.
Study: NCT06169072
Drug: Superparamagnetic Iron Oxide
Normalized name: Superparamagnetic iron oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension. In this study injected intradermally in an ultra-low dose
Study: NCT05451667
Drug: YJ001 for Spray Use
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: YJ001 (active ingredient)
Study: NCT05451667
Drug: Placebo of YJ001 for Spray Use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxypropyl Methylcellulose